Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Millington Financial Advisors LLC

Millington Financial Advisors LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,352 shares of the company’s stock after acquiring an additional 194 shares during the quarter. Novo Nordisk A/S accounts for 1.2% of Millington Financial Advisors LLC’s portfolio, making the stock its 25th largest position. Millington Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,485,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. CNB Bank bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $26,000. Pacific Center for Financial Services boosted its stake in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth about $28,000. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after acquiring an additional 141 shares in the last quarter. Finally, Bell Investment Advisors Inc lifted its holdings in Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 2.7 %

Shares of Novo Nordisk A/S stock traded up $3.36 during midday trading on Tuesday, hitting $128.62. The company’s stock had a trading volume of 3,701,385 shares, compared to its average volume of 4,856,259. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $577.19 billion, a P/E ratio of 47.55, a PEG ratio of 2.05 and a beta of 0.41. The stock has a 50-day simple moving average of $126.66 and a 200-day simple moving average of $111.54.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is currently 49.17%.

Analyst Ratings Changes

NVO has been the topic of several recent research reports. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. UBS Group started coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.